Ventyx Biosciences Inc (VTYX) Stock Price, Quote & News

Company Profile

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimo...

Industry: Biotechnology

Sector: Healthcare

Phone: 760-407-6511

Website: ventyxbio.com

Address:

12790 El Camino Real, Suite 200, San Diego, United States

DragonAlgo Mar. 12 at 6:20 AM

🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-03-20 | Strike: $15.00 | Type: CALL Option Plan (premium): Entry: $0.04 Stop: $0.03 TP1: $0.05 TP2: $0.07 TP3: $0.10 🔗 https://dragonalgo.com

0 · Reply

DragonAlgo Mar. 11 at 1:56 PM

🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-03-20 | Strike: $14.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 Volatility regime is active. 🔗 https://dragonalgo.com

0 · Reply

DragonAlgo Mar. 10 at 6:41 PM

🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-03-20 | Strike: $14.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 System-defined risk profile. 🔗 https://dragonalgo.com

0 · Reply

DragonAlgo Mar. 9 at 11:57 PM

🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-03-20 | Strike: $14.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 System-defined risk profile. 🔗 https://dragonalgo.com

0 · Reply

supertech1 Mar. 9 at 2:27 PM

$VTYX what’s going on …should I get rid of it?

0 · Reply

DragonAlgo Mar. 9 at 1:39 AM

0 · Reply

DragonAlgo Mar. 6 at 8:59 PM

0 · Reply

stockbuyer1234 Mar. 6 at 12:29 PM

$VTYX I still see the march call options on my Schwabb.Did they close the transaction?

3 · Reply

DragonAlgo Mar. 6 at 1:48 AM

0 · Reply

DragonAlgo Mar. 5 at 8:19 AM

0 · Reply

Halper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their Rights

SNCY

Jan 8, 2026, 11:44 AM EST - 2 months ago

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)

Jan 8, 2026, 11:01 AM EST - 2 months ago

Pharma stocks are set to take off this year, says UBS' Michael Yee

IBB LLY

Jan 7, 2026, 4:25 PM EST - 2 months ago

Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal

LLY

Jan 7, 2026, 4:17 PM EST - 2 months ago

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

LLY

Jan 6, 2026, 3:48 PM EST - 2 months ago

Lilly in talks to buy Ventyx Biosciences in more than $1 billion deal, WSJ reports

LLY

Jan 6, 2026, 3:40 PM EST - 2 months ago

Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter

LLY

Dec 2, 2025, 7:02 AM EST - 3 months ago

Ventyx Provides Clinical and Corporate Updates

Dec 1, 2025, 7:02 AM EST - 3 months ago

Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 7:02 AM EST - 4 months ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 4:02 PM EST - 4 months ago

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Oct 24, 2025, 2:17 AM EDT - 5 months ago

Ventyx Biosciences, Inc. (VTYX) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors Transcript

Oct 22, 2025, 4:02 PM EDT - 5 months ago

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Aug 27, 2025, 7:02 AM EDT - 7 months ago

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Jun 17, 2025, 7:00 AM EDT - 9 months ago

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

May 28, 2025, 8:00 AM EDT - 10 months ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

May 8, 2025, 4:01 PM EDT - 11 months ago

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Feb 27, 2025, 4:05 PM EST - 1 year ago

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Feb 18, 2025, 8:00 AM EST - 1 year ago

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 14, 2025, 8:00 AM EST - 1 year ago

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Nov 4, 2024, 10:32 AM EST - 1 year ago

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Sep 23, 2024, 11:13 AM EDT - 1 year ago

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

SNY

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Departure of Chief Financial Officer

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Jul 29, 2024, 2:31 PM EDT - 1 year ago

Dow Edges Lower; Ventyx Biosciences Shares Plummet

Jul 29, 2024, 11:03 AM EDT - 1 year ago

Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further

Jun 24, 2024, 6:00 AM EDT - 1 year ago

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details

Jun 21, 2024, 4:15 PM EDT - 1 year ago

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details

Jun 20, 2024, 7:20 AM EDT - 1 year ago

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

Jun 19, 2024, 4:20 PM EDT - 1 year ago

VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses

Jun 18, 2024, 3:42 PM EDT - 1 year ago

VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

Jun 17, 2024, 6:32 AM EDT - 1 year ago

VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 13, 2024, 4:06 PM EDT - 1 year ago

BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

DragonAlgo Mar. 12 at 6:20 AM

0 · Reply

DragonAlgo Mar. 11 at 1:56 PM

0 · Reply

DragonAlgo Mar. 10 at 6:41 PM

🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-03-20 | Strike: $14.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 System-defined risk profile. 🔗 https://dragonalgo.com

0 · Reply

DragonAlgo Mar. 9 at 11:57 PM

🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-03-20 | Strike: $14.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 System-defined risk profile. 🔗 https://dragonalgo.com

0 · Reply

supertech1 Mar. 9 at 2:27 PM

$VTYX what’s going on …should I get rid of it?

0 · Reply

DragonAlgo Mar. 9 at 1:39 AM

0 · Reply

DragonAlgo Mar. 6 at 8:59 PM

0 · Reply

stockbuyer1234 Mar. 6 at 12:29 PM

$VTYX I still see the march call options on my Schwabb.Did they close the transaction?

3 · Reply

DragonAlgo Mar. 6 at 1:48 AM

0 · Reply

DragonAlgo Mar. 5 at 8:19 AM

0 · Reply

ians Mar. 4 at 7:16 PM

$VTYX $VKTX CONGRATS to LT shareholders. 👍 LLY just knows how to pick em early. Wish we could have demanded more but mgmt had no bargaining power w/o a white knight in the form of SNY. 🤷‍♂️ Nonetheless, I was correct VTYX turned out to be the next VKTX. Just didn't think it would get taken out sooner than VKTX. The ? Now is which BP will BO VKTX & for how much 🤔☘️💎 https://stocktwits.com/ians/message/586903018

0 · Reply

Viktor4o Mar. 4 at 12:38 PM

$VTYX How long its been halted for?

1 · Reply

DragonAlgo Mar. 4 at 11:00 AM

🐉 $VTYX CALL — DragonAlgo® Signal Contract: VTYX CALL Expiry: 2026-04-17 | Strike: $14.00 | Type: CALL Option Plan (premium): Entry: $0.01 Stop: $0.01 TP1: $0.01 TP2: $0.02 TP3: $0.02 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

NorthStarStats Mar. 4 at 10:52 AM

Market is full of failed breakout and rug pulls. Be careful. From the scanner: $IDYA Score: 98.00, $TGT Score: 73.00, $DAY Score: 70.00, $VTYX Score: 70, $RTX Score: 68.00

2 · Reply

FreeBeerTomorrow Mar. 4 at 8:30 AM

$VTYX VTYX- Acquisition Approval: Shareholders officially approved the merger with Eli Lilly on March 3, 2026. Merger Details: Eli Lilly is acquiring VTYX for $14.00 per share in an all-cash deal. What Happens to the Stock: Once the merger is finalized (expected in the first half of 2026), VTYX will stop trading on the NASDAQ and become a wholly-owned subsidiary of Eli Lilly.

0 · Reply

Elevate1 Mar. 4 at 8:16 AM

$VTYX amazing the bulk is the shareholders approved with 44 million shareholders voting and only about 1.6 million voting against. I guess myself and my institutional friends will be all alone in our minority appraisal. Well we will be the only ones to share those benefits. It will be a while but will be lucrative. In the meantime Lly stock should be bought they now control the whole inflammatory cascade and NVO will now be cut in half from here in 6 months. PFE’s metsera purchase worth 90% less!

1 · Reply

StockNews_Live Mar. 4 at 12:53 AM

$VTYX ==> Halt Alert <== Symbol: #1 VTYX Halt Date: 03/03/2026 Halt Time: 19:50:00 Halt Type: (T12) Halt Down 🔴 Last Price: $13.99

0 · Reply

Viktor4o Mar. 3 at 10:42 PM

$VTYX Sad news, I was expecting higher bid 😕

2 · Reply

TwongStocks Mar. 3 at 10:14 PM

$VTYX With shareholders approving the merger, today will be the last day of trading. Expect NASDAQ to halt trading in VTYX at 7:50pm ET tonight 👇

1 · Reply

petr2022 Mar. 3 at 10:13 PM

$VTYX Approved overwhelmingly.

1 · Reply

TwongStocks Mar. 3 at 10:10 PM

$VTYX Merger proposal with $LLY approved by shareholders https://www.sec.gov/ix?doc=/Archives/edgar/data/0001851194/000119312526088654/d53134d8k.htm

0 · Reply

Viktor4o Mar. 3 at 9:22 PM

$VTYX Still nothing?

0 · Reply

Market Cap	1.00B
Revenue (ttm)	0.00
Net Income (ttm)	-135.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,448,800
Avg Vol	4,041,894
Day's Range	N/A - N/A
Shares Out	71.76M
Stochastic %K	100%
Beta	1.26
Analysts	Hold
Price Target	$13.44